Genmab A/S (GNMSF)
OTCMKTS
· Delayed Price · Currency is USD
188.80
-8.65 (-4.38%)
May 13, 2025, 9:55 AM EDT
Genmab Revenue
Genmab had revenue of 715.00M DKK in the quarter ending March 31, 2025, with 18.57% growth. This brings the company's revenue in the last twelve months to 21.64B, up 51.92% year-over-year. In the year 2024, Genmab had annual revenue of 21.53B with 30.67% growth.
Revenue (ttm)
21.64B DKK
Revenue Growth
+51.92%
P/S Ratio
3.84
Revenue / Employee
8.07M DKK
Employees
2,682
Market Cap
12.03B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Genmab News
- 1 day ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - Business Wire
- 1 day ago - Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire
- 3 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 6 days ago - Genmab reports Q1 results - Seeking Alpha
- 7 days ago - Genmab Announces Financial Results for the First Quarter of 2024 - GlobeNewsWire
- 10 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 13 days ago - Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) - Business Wire
- 17 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire